Piramal Alternatives, the investment arm of the Piramal Group’s fund management division, injected ₹110 crore into Biodeal Pharmaceuticals Limited, a contract development and manufacturing company.
The investment, facilitated through convertible instruments from its performing credit fund, is earmarked to bolster infrastructure, upgrade technological capabilities, and establish a dedicated facility for manufacturing nutraceuticals. Biodeal holds a significant position in the contract manufacturing sector, catering to a diverse clientele base.
Known for its production of nasal sprays for both international and domestic pharmaceutical giants, the company got approval under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2024. As reported by msn.com, its product range spans various dosage formats including dry powder inhalation capsules, tablets, ointments, lotions, and dusting powder.
